These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 1385995)
21. A study comparing paroxetine placebo and imipramine in depressed patients. Feighner JP; Cohn JB; Fabre LF; Fieve RR; Mendels J; Shrivastava RK; Dunbar GC J Affect Disord; 1993 Jun; 28(2):71-9. PubMed ID: 8354771 [TBL] [Abstract][Full Text] [Related]
22. [Imipramine in the treatment of painful diabetic neuropathy of the extremities]. Kvinesdal B; Molin J; Frøland A; Gram LF Ugeskr Laeger; 1983 Sep; 145(39):3018-9. PubMed ID: 6359618 [No Abstract] [Full Text] [Related]
23. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. Feighner JP Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():31-5. PubMed ID: 1431008 [TBL] [Abstract][Full Text] [Related]
24. Cardiovascular effects of paroxetine. Kuhs H; Rudolf GA Psychopharmacology (Berl); 1990; 102(3):379-82. PubMed ID: 2147517 [TBL] [Abstract][Full Text] [Related]
25. The predictive value of the dexamethasone suppression test. A placebo-controlled study. Peselow ED; Stanley M; Filippi AM; Barouche F; Goodnick P; Fieve RR Br J Psychiatry; 1989 Nov; 155():667-72. PubMed ID: 2532946 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study. Suominen J; Tamminen T; Elosuo R; Manniche PM Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246 [TBL] [Abstract][Full Text] [Related]
27. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805 [TBL] [Abstract][Full Text] [Related]
28. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Ohrberg S; Christiansen PE; Severin B; Calberg H; Nilakantan B; Borup A; Søgaard J; Larsen SB; Loldrup D; Bahr B Acta Psychiatr Scand; 1992 Dec; 86(6):437-44. PubMed ID: 1471536 [TBL] [Abstract][Full Text] [Related]
29. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y; Bentkover J; Schainbaum S; Manners S Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716 [TBL] [Abstract][Full Text] [Related]
30. Activation and inhibition of the endogenous opioid system in human heart failure. Oldroyd KG; Gray CE; Carter R; Harvey K; Borland W; Beastall G; Cobbe SM Br Heart J; 1995 Jan; 73(1):41-8. PubMed ID: 7888260 [TBL] [Abstract][Full Text] [Related]
31. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Arminen SL; Ikonen U; Pulkkinen P; Leinonen E; Mahlanen A; Koponen H; Kourula K; Ryyppö J; Korpela V; Lehtonen ML Acta Psychiatr Scand; 1994 Jun; 89(6):382-9. PubMed ID: 8085467 [TBL] [Abstract][Full Text] [Related]
34. The paroxetine 352 bipolar trial: A study in medical ghostwriting. Amsterdam JD; McHenry LB Int J Risk Saf Med; 2012; 24(4):221-31. PubMed ID: 23135337 [TBL] [Abstract][Full Text] [Related]
35. Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Cortés R; Soriano E; Pazos A; Probst A; Palacios JM Neuroscience; 1988 Nov; 27(2):473-96. PubMed ID: 2975361 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697 [TBL] [Abstract][Full Text] [Related]